OnKure Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.58
- 52-Week Range
- $2.01 – $5.38
- Market Cap
- $116.15M
- P/E (TTM)
- —
- EPS (TTM)
- -2.07
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.72
- PEG Ratio
- —
- Return on Equity
- -55.18%
- Return on Assets
- -34.38%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 18.84
- Debt/Equity
- 0.01
- Total Debt
- $790.00K
- Free Cash Flow
- $-26.37M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-48.30M
Market Snapshot
About
OnKure Therapeutics, Inc. is a precision oncology company developing targeted cancer therapies. The company focuses on novel small molecule inhibitors designed to address critical oncogenic drivers and resistance mechanisms in various tumor types.